Novartis

Valuation Analysis

About the Company

Novartis en bref

Novartis (NOVN.SW) is currently trading at 126,60 CHF with a market capitalization of 208,6 Md €. The trailing P/E ratio stands at 23.53x, with a forward P/E of 16x. The 52-week range spans from 91,56 CHF to 131,50 CHF ; the current price is 3.7% below the yearly high. Year-over-year revenue growth stands at +0.8%. The net profit margin stands at 22.5%.

💰 Dividende

Novartis pays an annual dividend of 3,70 CHF per share, representing a yield of 2.92%. The payout ratio stands at 69.86%.

📊 Avis des analystes

21 analystes évaluent Novartis (NOVN.SW) au consensus : Conserver. L'objectif de cours moyen est de 124,20 CHF , soit un potentiel de -1.9% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 94,57 CHF à 141,02 CHF .

Novartis : la thèse d'investissement en détail

Novartis (NOVN.SW) operates in the Healthcare — specifically Drug Manufacturers - General — and is headquartered in Switzerland. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

With a gross margin near 74.98%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Return on equity of 30.35% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard. Free cash flow is positive and net margins stand at 22.5%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.

Le scénario baissier

Revenue growth has slowed to just 0.8%, which is below nominal GDP — the business is no longer outgrowing the broader economy.

Valorisation en contexte

At a PEG of 3.55, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here.

À surveiller

• The forward P/E of 16x is meaningfully below the trailing 23.53x — analysts expect earnings to step up; the next earnings release is the test.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, higher leverage relative to equity.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Novartis?

Compare top-rated brokers — low fees, trusted providers, fully regulated.